MYDA Advisors LLC bought a new position in Viveve Medical Inc (NASDAQ:VIVE) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 85,000 shares of the company’s stock, valued at approximately $422,000. MYDA Advisors LLC owned 0.44% of Viveve Medical as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. bought a new position in shares of Viveve Medical in the 2nd quarter valued at about $189,000. California State Teachers Retirement System purchased a new stake in Viveve Medical in the 2nd quarter worth about $190,000. Teachers Advisors LLC purchased a new stake in Viveve Medical in the 2nd quarter worth about $196,000. Wells Fargo & Company MN raised its position in Viveve Medical by 135.1% in the 4th quarter. Wells Fargo & Company MN now owns 37,727 shares of the company’s stock worth $188,000 after purchasing an additional 21,683 shares during the period. Finally, TIAA CREF Investment Management LLC purchased a new stake in Viveve Medical in the 2nd quarter worth about $296,000. 40.60% of the stock is owned by institutional investors and hedge funds.
Viveve Medical Inc (NASDAQ VIVE) traded down $0.05 during trading hours on Wednesday, hitting $4.20. 113,592 shares of the stock traded hands, compared to its average volume of 280,861. Viveve Medical Inc has a 1-year low of $3.30 and a 1-year high of $11.16. The company has a quick ratio of 3.63, a current ratio of 3.89 and a debt-to-equity ratio of 2.72. The firm has a market capitalization of $130.48, a P/E ratio of -1.95 and a beta of -0.79.
A number of analysts recently weighed in on VIVE shares. Ladenburg Thalmann Financial Services reissued a “buy” rating on shares of Viveve Medical in a research report on Thursday, January 4th. Mizuho reaffirmed a “buy” rating and set a $10.00 target price on shares of Viveve Medical in a research report on Thursday, February 1st. ValuEngine lowered shares of Viveve Medical from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Finally, Northland Securities started coverage on shares of Viveve Medical in a research report on Friday, January 5th. They set an “outperform” rating and a $8.00 target price on the stock. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. Viveve Medical presently has an average rating of “Buy” and an average target price of $10.00.
WARNING: This story was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://ledgergazette.com/2018/03/14/myda-advisors-llc-invests-422000-in-viveve-medical-inc-vive-stock.html.
Viveve Medical Company Profile
Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.